申请人:The Upjohn Company
公开号:US04514407A1
公开(公告)日:1985-04-30
Triazolo-benzodiazepine-1-ethanamines of the formulas ##STR1## where R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and Ring A are as defined in the specification, e.g., 8-chloro-N,N-dimethyl-.beta.,6-diphenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benz odiazepine-1-ethanamine, and pharmacologically acceptable salts thereof, have been found to have substantial diuretic, natriuretic, but little, if any, kaliuretic activity, which can be used alone, or concomittently with other diuretic drugs such as furosemide or hydrochlorothiazide and/or with antihypertensive agents such as propranolo, captopril, minoxidil, prazosin, guanadrel sulfate, whose actions are supplemented by the action of a diuretic drug.
Triazolo-苯二氮卓-1-
乙胺的分子式为##STR1##其中R、R.sub.1、R.sub.2、R.sub.3、R.sub.4和环A如规范中所定义,例如8-
氯-N,N-二甲基-β,6
-二苯基-4H-[1,2,4]三唑并[4,3-a][1,4]苯二氮卓-1-
乙胺及其药理学上可接受的盐,已被发现具有显著的利尿、排
钠作用,但几乎没有
钾排泄作用,可单独使用,或与其他
利尿药物如
呋塞米或
氢氯噻嗪以及/或抗高血压药物如
普萘洛尔、卡普托普利、
米诺地尔、普拉唑辛、瓜那德
雷酸盐同时使用,其作用被
利尿药物的作用所补充。